MEDICLIN AG (MED.DE) Stock Fundamental Analysis
Europe - FRA:MED - DE0006595101 - Common Stock
3.5 EUR
+0.02 (+0.57%)
We assign a fundamental rating of 6 out of 10 to MED. MED was compared to 31 industry peers in the Health Care Providers & Services industry. While MED belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on MED.
1. Profitability
1.1 Basic Checks
In the past year MED was profitable.
In the past year MED had a positive cash flow from operations.
In multiple years MED reported negative net income over the last 5 years.
MED had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of 3.76%, MED is doing good in the industry, outperforming 70.97% of the companies in the same industry.
With a decent Return On Equity value of 14.64%, MED is doing good in the industry, outperforming 77.42% of the companies in the same industry.
With a decent Return On Invested Capital value of 6.72%, MED is doing good in the industry, outperforming 70.97% of the companies in the same industry.
MED had an Average Return On Invested Capital over the past 3 years of 3.46%. This is below the industry average of 6.26%.
The 3 year average ROIC (3.46%) for MED is below the current ROIC(6.72%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.76% | ||
| ROE | 14.64% | ||
| ROIC | 6.72% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
1.3 Margins
Looking at the Profit Margin, with a value of 4.34%, MED is in the better half of the industry, outperforming 67.74% of the companies in the same industry.
MED's Profit Margin has improved in the last couple of years.
The Operating Margin of MED (8.17%) is better than 67.74% of its industry peers.
MED's Operating Margin has improved in the last couple of years.
MED has a better Gross Margin (83.90%) than 83.87% of its industry peers.
MED's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.17% | ||
| PM (TTM) | 4.34% | ||
| GM | 83.9% |
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MED is still creating some value.
The number of shares outstanding for MED remains at a similar level compared to 1 year ago.
The number of shares outstanding for MED remains at a similar level compared to 5 years ago.
Compared to 1 year ago, MED has an improved debt to assets ratio.
2.2 Solvency
MED has an Altman-Z score of 1.51. This is a bad value and indicates that MED is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MED (1.51) is comparable to the rest of the industry.
The Debt to FCF ratio of MED is 10.50, which is on the high side as it means it would take MED, 10.50 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of MED (10.50) is comparable to the rest of the industry.
MED has a Debt/Equity ratio of 1.84. This is a high value indicating a heavy dependency on external financing.
MED has a worse Debt to Equity ratio (1.84) than 70.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.84 | ||
| Debt/FCF | 10.5 | ||
| Altman-Z | 1.51 |
ROIC/WACC1.44
WACC4.68%
2.3 Liquidity
A Current Ratio of 1.82 indicates that MED should not have too much problems paying its short term obligations.
The Current ratio of MED (1.82) is better than 83.87% of its industry peers.
A Quick Ratio of 1.78 indicates that MED should not have too much problems paying its short term obligations.
With an excellent Quick ratio value of 1.78, MED belongs to the best of the industry, outperforming 90.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.78 |
3. Growth
3.1 Past
MED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 327.10%, which is quite impressive.
The Earnings Per Share has been growing by 20.79% on average over the past years. This is a very strong growth
MED shows a small growth in Revenue. In the last year, the Revenue has grown by 1.64%.
MED shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.19% yearly.
EPS 1Y (TTM)327.1%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%395.24%
Revenue 1Y (TTM)1.64%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%8.62%
3.2 Future
MED is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.85% yearly.
The Revenue is expected to grow by 2.80% on average over the next years.
EPS Next Y52.44%
EPS Next 2Y14.23%
EPS Next 3Y13.85%
EPS Next 5YN/A
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 4.93, the valuation of MED can be described as very cheap.
Based on the Price/Earnings ratio, MED is valued cheaper than 100.00% of the companies in the same industry.
MED is valuated cheaply when we compare the Price/Earnings ratio to 27.57, which is the current average of the S&P500 Index.
MED is valuated cheaply with a Price/Forward Earnings ratio of 6.48.
Based on the Price/Forward Earnings ratio, MED is valued cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.09. MED is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.93 | ||
| Fwd PE | 6.48 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MED is valued cheaper than 96.77% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MED indicates a rather cheap valuation: MED is cheaper than 87.10% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.83 | ||
| EV/EBITDA | 3.14 |
4.3 Compensation for Growth
MED's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MED may justify a higher PE ratio.
A more expensive valuation may be justified as MED's earnings are expected to grow with 13.85% in the coming years.
PEG (NY)0.09
PEG (5Y)0.24
EPS Next 2Y14.23%
EPS Next 3Y13.85%
5. Dividend
5.1 Amount
MED has a Yearly Dividend Yield of 1.18%.
Compared to an average industry Dividend Yield of 2.52, MED has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.32, MED's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.18% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y14.23%
EPS Next 3Y13.85%
FRA:MED (10/22/2025, 7:00:00 PM)
3.5
+0.02 (+0.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners1.54%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap166.25M
Revenue(TTM)781.85M
Net Income(TTM)33.96M
Analysts83.33
Price Target4.79 (36.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.18% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)26.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.93 | ||
| Fwd PE | 6.48 | ||
| P/S | 0.21 | ||
| P/FCF | 3.83 | ||
| P/OCF | 1.78 | ||
| P/B | 0.72 | ||
| P/tB | 0.8 | ||
| EV/EBITDA | 3.14 |
EPS(TTM)0.71
EY20.29%
EPS(NY)0.54
Fwd EY15.44%
FCF(TTM)0.91
FCFY26.09%
OCF(TTM)1.96
OCFY56.06%
SpS16.46
BVpS4.88
TBVpS4.37
PEG (NY)0.09
PEG (5Y)0.24
Graham Number8.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.76% | ||
| ROE | 14.64% | ||
| ROCE | 8.66% | ||
| ROIC | 6.72% | ||
| ROICexc | 8.86% | ||
| ROICexgc | 9.27% | ||
| OM | 8.17% | ||
| PM (TTM) | 4.34% | ||
| GM | 83.9% | ||
| FCFM | 5.55% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexgc growth 3Y64.29%
ROICexgc growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score8
Asset Turnover0.87
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.84 | ||
| Debt/FCF | 10.5 | ||
| Debt/EBITDA | 3.69 | ||
| Cap/Depr | 96.31% | ||
| Cap/Sales | 6.37% | ||
| Interest Coverage | 2.92 | ||
| Cash Conversion | 80.6% | ||
| Profit Quality | 127.75% | ||
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.78 | ||
| Altman-Z | 1.51 |
F-Score8
WACC4.68%
ROIC/WACC1.44
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)327.1%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%395.24%
EPS Next Y52.44%
EPS Next 2Y14.23%
EPS Next 3Y13.85%
EPS Next 5YN/A
Revenue 1Y (TTM)1.64%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%8.62%
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
EBIT growth 1Y377.48%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year131.21%
EBIT Next 3Y31.07%
EBIT Next 5YN/A
FCF growth 1Y195.08%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y96.79%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%